enterprise value $100m - lani superior tamiflu

Ridiculous situation here.

-----------------------------------

The developer of Tamiflu, Gilead Sciences, market cap gapped up US$1.5 billion in 2005, because Gilead cut a better royalties deal with Roche. Probably that $1.5b was overs...but not by much concerning the massive Tamiflu sales that would follow.

The TOTAL ie WHOLE size of Biota is US$85 million...when you deduct their cash, post 30 June.

-------------------------

Much independant world research suggesting the once only Lani "puff"...is a superior influenza anti-viral to serve as Government pandamic stockpile replacement, for "out of date Tamiflu.
--------------------------------------

Gilead and Roche End Tamiflu Dispute; Expanded FOSTER

CITY, Calif., Nov 16, 2005 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) and Roche today announced the companies have ended their dispute related to the companies' 1996 Development and License Agreement for Tamiflu(R) (oseltamivir phosphate). With increasing public concern over the threat of an influenza pandemic, in particular related to the growing incidence of avian influenza, Gilead and Roche have reached this settlement in the interest of working together to address public health needs.

---

Gilead receives a blended royalty on sales of Tamiflu, tiered from 14 to 22 percent based on Roche's annual net sales. Roche has agreed to eliminate the pre-existing contractual cost of goods adjustments from the royalty calculations, retroactive to calendar year 2004 and for all future calculations. ........